Article
Version 1
Preserved in Portico This version is not peer-reviewed
Application of fSP3 towards Non-Systemic Drug Discovery
Version 1
: Received: 28 August 2023 / Approved: 28 August 2023 / Online: 29 August 2023 (03:25:53 CEST)
How to cite: Benardout, M.; Le Gresley, A.; El Shaer, A.; Wren, S. P. Application of fSP3 towards Non-Systemic Drug Discovery. Preprints 2023, 2023081882. https://doi.org/10.20944/preprints202308.1882.v1 Benardout, M.; Le Gresley, A.; El Shaer, A.; Wren, S. P. Application of fSP3 towards Non-Systemic Drug Discovery. Preprints 2023, 2023081882. https://doi.org/10.20944/preprints202308.1882.v1
Abstract
Non-systemic oral drugs, which do not get absorbed through the gastrointestinal membrane, are an important group of compounds for targeting diseases residing within the gastrointestinal lumen. However, they require a set of design principles not sufficiently covered by traditional druglikeness metrics, such as Lipinski’s Rule of 5. These druglikeness metrics fail to accurately identify true negative outcomes; such is the requirement for novel cheminformatic based approaches for the discovery of non-systemic small molecules. One such example of these newer metrics is the fraction of SP3-hybridised carbon atoms (fSP3) which has shown promising application as an identifier of poor oral-bioavailability. Herein, we discuss the application of fSP3 in the drug discovery process in a number of case studies, including our own work discovering non-systemic fructose scavengers for the treatment of fructose malabsorption.
Keywords
fSP3; drug design; bioavailability; non-systemic drugs; druglikeness; cheminformatics
Subject
Chemistry and Materials Science, Medicinal Chemistry
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment